Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2003 2
2004 1
2005 3
2006 1
2009 4
2010 5
2011 3
2012 2
2013 2
2015 5
2016 2
2017 3
2019 1
2020 5
2021 3
2022 4
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

41 results

Results by year

Filters applied: . Clear all
Page 1
Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase III BALANCE study.
Wallace EL, Goker-Alpan O, Wilcox WR, Holida M, Bernat J, Longo N, Linhart A, Hughes DA, Hopkin RJ, Tøndel C, Langeveld M, Giraldo P, Pisani A, Germain DP, Mehta A, Deegan PB, Molnar MJ, Ortiz D, Jovanovic A, Muriello M, Barshop BA, Kimonis V, Vujkovac B, Nowak A, Geberhiwot T, Kantola I, Knoll J, Waldek S, Nedd K, Karaa A, Brill-Almon E, Alon S, Chertkoff R, Rocco R, Sakov A, Warnock DG. Wallace EL, et al. Among authors: vujkovac b. J Med Genet. 2023 Nov 8:jmg-2023-109445. doi: 10.1136/jmg-2023-109445. Online ahead of print. J Med Genet. 2023. PMID: 37940383 Free article.
Biomarkers of Fabry Nephropathy: Review and Future Perspective.
Levstek T, Vujkovac B, Trebusak Podkrajsek K. Levstek T, et al. Among authors: vujkovac b. Genes (Basel). 2020 Sep 18;11(9):1091. doi: 10.3390/genes11091091. Genes (Basel). 2020. PMID: 32962051 Free PMC article. Review.
Podocyturia in Fabry disease: a 10-year follow-up.
Vujkovac B, Srebotnik Kirbiš I, Keber T, Cokan Vujkovac A, Tretjak M, Radoš Krnel S. Vujkovac B, et al. Clin Kidney J. 2021 Sep 16;15(2):269-277. doi: 10.1093/ckj/sfab172. eCollection 2022 Feb. Clin Kidney J. 2021. PMID: 35145641 Free PMC article.
Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study.
Linhart A, Dostálová G, Nicholls K, West ML, Tøndel C, Jovanovic A, Giraldo P, Vujkovac B, Geberhiwot T, Brill-Almon E, Alon S, Chertkoff R, Rocco R, Hughes D. Linhart A, et al. Among authors: vujkovac b. Orphanet J Rare Dis. 2023 Oct 21;18(1):332. doi: 10.1186/s13023-023-02937-6. Orphanet J Rare Dis. 2023. PMID: 37865771 Free PMC article.
Characteristics of Vascular Phenotype in Fabry Patients.
Vujkovac AC, Vujkovac B, Novaković S, Števanec M, Šabovič M. Vujkovac AC, et al. Among authors: vujkovac b. Angiology. 2021 May;72(5):426-433. doi: 10.1177/0003319720981521. Epub 2020 Dec 21. Angiology. 2021. PMID: 33342225
41 results